Molecular mechanisms of Nrf2‐mediated antioxidant response

Molecular Carcinogenesis - Tập 48 Số 2 - Trang 91-104 - 2009
Wenge Li1, Ah‐Ng Tony Kong2
1Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
2Ernest Mario School of Pharmacy, Pharmaceutics

Tóm tắt

AbstractNrf2 is the key transcription factor regulating the antioxidant response. Nrf2 signaling is repressed by Keap1 at basal condition and induced by oxidative stress. Keap1 is recently identified as a Cullin 3‐dependent substrate adaptor protein. A two‐sites binding “hinge & latch” model vividly depicts how Keap1 can efficiently present Nrf2 as substrate for ubiquitination. Oxidative perturbation can impede Keap1‐mediated Nrf2 ubiquitination but fail to disrupt Nrf2/Keap1 binding. Nrf2 per se is a redox‐sensitive transcription factor. A new Nrf2‐mediated redox signaling model is proposed based on these new discoveries. Free floating Nrf2 protein functions as a redox‐sensitive probe. Keap1 instead functions as a gate keeper to control the availability of Nrf2 probes and thus regulates the overall sensitivity of the redox signaling. © 2008 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/j.molmed.2004.09.003

10.2174/1389200054633826

10.2174/138920006778017795

10.1096/fj.04-2591hyp

10.1080/03602530600971974

10.1158/0008-5472.CAN-05-3823

10.1158/0008-5472.CAN-06-0300

10.1158/0008-5472.CAN-04-1906

10.1093/carcin/24.3.461

Martinez‐Sanchez G, 2007, Cellular redox status regulates hypoxia inducible factor‐1 activity. Role in tumour development, J Exp Clin Cancer Res, 26, 39

10.1111/j.1749-6632.1996.tb52944.x

10.1023/B:MCBI.0000044378.09409.b5

10.1016/j.abb.2006.08.005

10.1096/fj.05-4401fje

10.1016/j.freeradbiomed.2004.02.075

10.1074/jbc.M312492200

Park EY, 2005, NO signaling in ARE‐mediated gene expression, Methods Enzymol, 396, 341, 10.1016/S0076-6879(05)96028-X

10.1021/tx050217c

10.1073/pnas.91.21.9926

10.1016/j.abb.2004.10.012

10.1046/j.1365-2443.2001.00469.x

10.1128/MCB.25.24.10895-10906.2005

10.1074/jbc.M403061200

10.1101/gad.13.1.76

10.1038/sj.onc.1204506

10.1073/pnas.0307301101

10.1016/j.bbrc.2005.10.185

10.1038/ng1248

10.1073/pnas.0308347100

10.1002/cm.10025

10.1124/mol.62.5.1001

10.1128/MCB.25.3.1089-1099.2005

10.1128/MCB.25.11.4501-4513.2005

10.1128/MCB.23.22.8137-8151.2003

10.1128/MCB.00630-07

10.1128/MCB.24.19.8477-8486.2004

10.1128/MCB.25.1.162-171.2005

10.1128/MCB.24.16.7130-7139.2004

10.1128/MCB.24.24.10941-10953.2004

10.1073/pnas.172398899

10.1128/MCB.15.8.4184

10.1016/S0378-1119(02)00788-6

10.1111/j.1365-2443.2006.00965.x

10.1016/S0021-9258(18)99004-6

10.1073/pnas.87.16.6258

10.1146/annurev.pharmtox.43.100901.140229

Talalay P, Chemoprotection against cancer by phase 2 enzyme induction, Toxicol Let, 173

10.1021/bi047434h

10.1073/pnas.0502402102

10.1021/bi00526a001

10.1074/jbc.M410073200

10.1021/tx0502138

10.1074/jbc.M503346200

10.1042/bj20031049

10.1128/MCB.26.8.2887-2900.2006

10.1128/MCB.26.1.221-229.2006

10.1074/jbc.M601119200

10.1074/jbc.M300931200

10.1016/S1097-2765(01)00347-1

10.1038/nrm1547

10.1515/BC.2006.164

10.1046/j.1365-2443.2002.00561.x

10.1128/MCB.00753-07

10.1038/sj.emboj.7601243

10.1016/j.molcel.2006.01.013

10.1074/jbc.M206530200

10.1074/jbc.M501279200

10.1002/mc.20234

10.1128/MCB.24.8.3473-3484.2004

10.1074/jbc.M502083200

10.1074/jbc.M410601200

10.1074/jbc.M709040200

10.1016/0092-8674(95)90436-0

10.1016/0092-8674(95)90435-2

10.1074/jbc.M602746200

10.1128/MCB.22.18.6321-6335.2002

10.1016/S0022-2836(75)80119-7

10.1021/bi00072a001

10.1074/jbc.M511198200

10.1074/jbc.M611336200

10.1074/jbc.M513737200

10.1006/bbrc.2001.5944

10.1074/jbc.M401368200

10.1128/MCB.25.10.4150-4165.2005

10.1038/sj.onc.1205288

10.1124/jpet.103.064261

10.1093/emboj/17.24.7416

10.1074/jbc.275.20.15370

10.1128/MCB.21.18.6139-6150.2001

10.1042/BJ20050439

10.1146/annurev.pharmtox.45.120403.095857

10.1093/toxsci/kfh231

10.1038/ng1103-202

10.1124/mol.107.035360

10.1074/jbc.M606539200

10.1073/pnas.0607260103

10.1074/jbc.M004037200

10.1074/jbc.274.39.27545

10.1158/0008-5472.CAN-05-3513

10.1158/1535-7163.MCT-05-0497

10.1016/j.freeradbiomed.2004.07.021

10.1074/jbc.M408275200

10.1007/s11095-006-9094-2

10.1074/jbc.275.4.2322

10.1074/jbc.M206911200

10.1074/jbc.M307633200

10.1152/ajpcell.00043.2003

10.1128/MCB.02065-06

10.1074/jbc.M100734200

10.1128/MCB.23.20.7198-7209.2003

10.1016/j.freeradbiomed.2007.03.001

10.1128/MCB.26.4.1235-1244.2006

Gao L, 2006, Novel N‐3 fatty acid oxidation products activate Nrf2 by destabilizing the association between keap1 and cullin3, J Biol Chem

10.1073/pnas.90.23.11371

10.1074/jbc.274.10.6443

10.1074/jbc.M602802200

10.1042/BJ20060725

10.1074/jbc.M314219200

10.1038/356260a0

10.1016/j.toxlet.2006.10.012

10.1016/j.tips.2005.04.004